ResMed Inc. Announces Record Financial Results for the Quarter Ended Septembe...(ained by contacting Connie Bienfait at R...),Health

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the US Securities & Exchange Commission. Those reports are available on the Company's Web site.

                         RESMED INC AND SUBSIDIARIES
                Consolidated Statements of Income (Unaudited)
                  (In US$ thousands, except per share data)


                                                  Three Months Ended
                                                     September 30,
                                                   2009          2008
                                                   ----          ----

    Net revenue                                $246,992      $217,931
    Cost of sales                                96,814        90,804
    -------------                                ------        ------
    Gross profit                                150,178       127,127
    ------------                                -------       -------

    Operating expenses
    Selling, general and administrative          76,756        71,337
    Research and development                     17,914        17,293
    Amo
'/>"/>
SOURCE  ResMed Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 
Related medicine technology :

1. ResMed Acquires Laboratoires Narval
2. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
4. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
5. OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010
6. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
7. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
8. GSI Group Inc. Announces NASDAQ Delisting and Reports Progress on Revenue Recognition Review and Preliminary Third Quarter 2009 Bookings and Cash Balance
9. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
10. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
11. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF